Identification of differentially expressed genes in cervical cancer by bioinformatics analysis

Ge, Yanshan; Zhang, Chaoyang; Xiao, Songshu; Liang, Lin; Liao, Shan; Xiang, Yanqi; Cao, Ke; Chen, Hongxiang; Zhou, Yanhong

doi:10.3892/ol.2018.8953

Cited by 14 publications

(16 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a result of the limited therapeutic schemes, CC is still a major threat to women's health. Thus, further investigations of the molecular mechanisms are necessary …”

Section: Introductionmentioning

confidence: 99%

“…Thus, further investigations of the molecular mechanisms are necessary. 6 Increasing studies focus on the function and underlying mechanism of long non-coding RNA (lncRNA) in human tumors. [7][8][9] As a member of non-coding RNA (ncRNA) family, lncRNA is defined as the RNA transcripts with a length > 200 nucleotides, which is differentiated from other ncRNAs, such as microRNA and transfer RNA.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ELK1‐activated GPC3‐AS1/GPC3 axis promotes the proliferation and migration of cervical cancer cells

Zhu

2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

Background Long non‐coding RNA (lncRNA) is reported to be involved in multiple biological processes in numerous human tumors. Furthermore, an increasing number of studies have confirmed the involvement of lncRNA in the initiation and development of human cancers, including cervical cancer (CC). Methods The present study explored the potential role of lncRNA glypican 3 antisense transcript 1 (GPC3‐AS1) with respect to regulating CC cell proliferation and migration. Results A quantitative reverse transcriptase‐polymerase chain reaction confirmed that GPC3‐AS1 was up‐regulated in CC cells compared to normal CRL‐2614 cells. Loss‐of‐function assays demonstrated the negative effect of GPC3‐AS1 depletion on CC cell proliferation and migration. GPC3‐AS1 positively regulated its nearby gene glypican 3 (GPC3). Significant up‐regulation of GPC3 was also observed in CC cells, consistently with GPC3‐AS1. In addition, GPC3‐AS1 and GPC3 synergistically promoted the proliferative and migratory abilities of CC cells. Mechanistic investigation showed that ELK1 acted as the transcription activator of GPC3‐AS1 and GPC3, thus contributing to their up‐regulation in CC cells. Rescue assays indicated that the ELK1‐induced GPC3‐AS1/GPC3 axis promoted cell proliferation and migration in CC. Conclusions The results of the present study have revealed a novel molecular pathway that can regulate CC cell proliferation and migration, thus providing a new basis for investigating the molecular mechanism associated with CC progression.

show abstract

“…As a result of the limited therapeutic schemes, CC is still a major threat to women's health. Thus, further investigations of the molecular mechanisms are necessary …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

ELK1‐activated GPC3‐AS1/GPC3 axis promotes the proliferation and migration of cervical cancer cells

Zhu

2019

The Journal of Gene Medicine

View full text Add to dashboard Cite

show abstract

“…Until now, the detection of drug resistance mainly relies on Sanger automated sequencing and second-generation sequencing (NGS), and NGS is an emerging technology with great potential in data analysis and data integrity [78]. Of note, international guidelines recommend that RAS present in >15% of sequences are believed clinically significant and should be taken into serious consideration in the selection of treatment regimen [102,103].Conversely, in a RAS study based on massively parallel, they reported that presence of baseline RASs even much less than 15% of HCV sequences is also associated with treatment failure in two HCV G1a-infected patients treated with ledipasvir (LED)+ sofosbuvir (SOF) [67,[104][105][106].…”

Section: Drug Resistancementioning

confidence: 99%

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Zeng¹,

Li²,

Hou³

et al. 2020

Int. J. Med. Sci.

View full text Add to dashboard Cite

Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance.

show abstract

“…Five hundred and thirty-three patients were randomly assigned to the training set (n = 350) and validation set (n = 183). The GEO (http://www.ncbi.nlm.nih.gov/geo/) database, a comprehensive library of gene expression, is a free public database (23)(24)(25)(26). Using "ccRCC" as the search term, relevant data sets were screened from the GEO database.…”

Section: Patient Datamentioning

confidence: 99%

The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma

Mou

Zhang

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: Clear cell renal cell carcinoma (ccRCC) is characteristics of resistance to chemotherapy and radiotherapy. The prognosis of ccRCC was dismay with immense diversity. Iron metabolism disturbance is a common phenomenon in ccRCC. The purpose of our study is to identify and validate the candidate prognostic gene signature of iron metabolism and methylation closely related to the poor prognosis of ccRCC through comprehensive bioinformatics analysis in The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Methods: The prognostic iron metabolism-related genes were screened according to the overlapping differentially expressed genes (DEGs) from the TCGA database. We built a prognostic model using risk score method to predict OS, each ccRCC patient's risk score was calculated, and the resulting score can divide these patients into two categories according to the cut-point risk score. The prognostic significance of the hub genes was further evaluated with the Kaplan-Meier (KM) survival and Receiver Operating Characteristic (ROC) curve analysis. Univariate and multivariate Cox regression analysis was implemented to evaluate the impact of each variable on OS. Furthermore, the prediction power of the 25 gene signatures has been validated using an independent ccRCC cohort from the GEO database. The Gene Set Enrichment Analysis (GSEA) identified the characteristics of hub related oncogenes. Finally, we utilize Weighted Gene Co-expression Network Analysis (WGCNA) to investigate the co-expression network based on these DEGs. Results: In this study, we identified and validated 25 iron metabolism-related and methylated genes as the prognostic signatures, which differentiated ccRCC patients into high and low risk subgroups. The KM analysis showed that the survival rate of the high-risk patients was significantly lower than that of the low-risk patients. The risk score calculated with 25 gene signatures could largely predict OS and DFS for 1, 3, and 5 years in patients with ccRCC. Mou et al. Iron Metabolism Gene Predicts Prognosis in ccRCC Conclusions: Taken together, we identified the key iron metabolism-related and methylated genes for ccRCC through a comprehensive bioinformatics analysis. This study provides a reliable and robust gene signature for the prognostic predictor of ccRCC patients and maybe provides a promising treatment strategy for this lethal disease.

show abstract

Identification of differentially expressed genes in cervical cancer by bioinformatics analysis

Cited by 14 publications

References 52 publications

ELK1‐activated GPC3‐AS1/GPC3 axis promotes the proliferation and migration of cervical cancer cells

ELK1‐activated GPC3‐AS1/GPC3 axis promotes the proliferation and migration of cervical cancer cells

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

The Landscape of Iron Metabolism-Related and Methylated Genes in the Prognosis Prediction of Clear Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About